Table 2.
Treatment | Initiation (5-week protocol) | Promotion (15-week protocol) | ||||
---|---|---|---|---|---|---|
Relative organ weight | Relative organ weight | |||||
Liver | Spleen | Kidney | Liver | Spleen | Kidney | |
NSS | 4.02 ± 0.21 | 0.66 ± 0.03 | 0.23 ± 0.04 | 3.16 ± 0.23 | 0.23 ± 0.04 | 0.51 ± 0.02 |
NSS + PRBE 500 mg kg−1 BW | 4.12 ± 0.18 | 0.68 ± 0.04 | 0.20 ± 0.02 | 2.94 ± 0.25 | 0.17 ± 0.03 | 0.49 ± 0.04 |
NSS + PCA 4 mg kg−1 BW | 4.32 ± 0.05 | 0.68 ± 0.03 | 0.24 ± 0.03 | 3.12 ± 0.19 | 0.18 ± 0.01 | 0.47 ± 0.03 |
DEN | 3.08 ± 0.14* | 0.66 ± 0.03 | 0.28 ± 0.04 | 3.06 ± 0.22 | 0.19 ± 0.02 | 0.53 ± 0.04 |
DEN + PRBE 500 mg kg−1 BW | 3.36 ± 0.11# | 0.68 ± 0.03 | 0.26 ± 0.03 | 3.12 ± 0.26 | 0.19 ± 0.02 | 0.53 ± 0.02 |
DEN + PCA 4 mg kg−1 BW | 3.50 ± 0.18# | 0.70 ± 0.03 | 0.29 ± 0.03 | 2.92 ± 0.10 | 0.19 ± 0.01 | 0.51 ± 0.02 |
Values are expressed as mean ± SD.
DEN: diethylnitrosamine, NSS: normal saline solution, PCA: protocatechuic acid, PRBE: purple rice bran extract.
*Significantly different from the negative control group, p < 0.05.
#Significantly different from the positive control group, p < 0.05.